CLAIMS

1. A compound of formula I

in free or salt or solvate form, where

-C~Y- denotes -CH₂-CH₂-, -CH=CH- or -CH₂-O-; one of R1 and R2 is hydroxy and the other is hydrogen;

G is a group having the formula Ia, Ib, Ic, Id or Ie

n1 is an integer from 0 to 4;

when n^1 is 0, R^a is $-CR^{26}R^{27}$ -, $-CH_2$ - CH_2 -, $-CH_2$ - CH_2 -, $-CH_2$ - CH_2 -, $-CH_2$ - CH_2 -, -CH₂-S-, -CH₂-CH₂-S-, -CH₂-SO-, -CH₂-SO₂- or a bond, and R^b is -CR²⁸R²⁹-, -CH₂-CH₂-CH₂-, -CH₂-O-, -CH₂-O-CH₂-, -CH₂-S-, -CH₂-CH₂-S-, -CH₂-SO-, -CH₂-SO₂- or a bond,

otherwise when n¹ is 1, 2, 3 or 4, R^a and R^b are independently -CR²⁶R²⁷-, -CH₂-CH₂-, -CH₂-CH₂-CH₂-, -O-, -CH₂-O-, -CH₂-O-CH₂-, -S-, -SO-, -SO₂-, -CH₂-S-, -CH₂-CH₂-S-, -CH2-SO-, -CH2-SO2- or a bond;

 R^c is hydrogen or C_1 - C_{10} -alkyl optionally substituted by a C_5 - C_{15} -carbocyclic group or by C1-C10-alkoxy,

or when Rb is -CR26R27- or -CR28R29-, Re and Rb form a C5-C15-carbocyclic group; R3, R4, R5 and R6 are independently hydrogen, halo, C1-C10-alkyl, C1-C10-alkoxy, or a 5- or 6-membered heterocyclic ring wherein at least one of the ring atoms is nitrogen, oxygen or sulphur, or any two of R3, R4, R5 and R6 that are attached to adjacent carbon atoms on the phenylene ring together form a phenylene ring, C3-C10-cycloalkyl, C3-C10-cycloalkenyl or 5or 6-membered heterocyclic ring wherein at least one of the ring atoms is nitrogen, oxygen

R²⁶, R²⁷ and R²⁸ are independently hydrogen, C₁-C₁₀-alkyl or C₁-C₁₀-alkoxy, either of which or sulphur; being optionally substituted by a Cs-C1s-carbocyclic group;

R²⁹ is C₁-C₁₀-alkyl or C₁-C₁₀-alkoxy, either of which being optionally substituted by a C₅-C15-carbocyclic group;

n² is an integer from 0 to 4;

C~C denotes C=C or CH-CH;

R⁷ is hydrogen or C₁-C₁₀-alkyl optionally substituted by a C₃-C₁₅-carbocyclic group or by C_1 - C_{10} -alkoxy;

R8 is hydrogen, hydroxy, C1-C10-alkyl or C1-C10-alkoxy;

R9 and R10 are independently hydrogen, halo, a C3-C15-carbocyclic group, a 5- or 6membered heterocyclic ring wherein at least one of the ring atoms is nitrogen, oxygen or sulphur, C1-C10-alkyl optionally substituted by a C3-C15-carbocyclic group, or C1-C10-alkoxy optionally substituted by a C3-C15-carbocyclic group,

or R^9 and R^{10} together form a C_3 - C_{10} -cycloalkyl or C_3 - C_{10} -cycloalkenyl in either case optionally substituted by C1-C10-alkyl or C1-C10-alkoxy;

R¹¹ is hydrogen, hydroxy, a C₃-C₁₅-carbocyclic group, C₁-C₁₀-alkyl optionally substituted by a C3-C15-carbocyclic group, or C1-C10-alkoxy optionally substituted by a C3-C15-carbocyclic group;

n³ is an integer from 0 to 4;

 R^{12} is C_1 - C_{10} -alkyl substituted by C_1 - C_{10} -alkoxy, C_7 - C_{15} -aralkyloxy, a C_5 - C_{15} -carbocyclic group or by a 5- or 6-membered heterocyclic ring wherein at least one of the ring atoms is nitrogen, oxygen or sulphur;

R¹³, R¹⁴, R¹⁵ and R¹⁶ are independently hydrogen, halo, cyano, carboxy, nitro, C₁-C₁₀-alkyl, C_2 - C_{10} -alkenyl, C_1 - C_{10} -alkoxy, C_7 - C_{15} -aralkyloxy, tri- C_1 - C_{10} -alkylsilyl, aminocarbonyl, amino, C1-C10-alkylamino, di(C1-C10-alkyl)amino, a C5-C15-carbocyclic group or a 5- or 6membered heterocyclic ring wherein at least one of the ring atoms is nitrogen, oxygen or

or any two of R13, R14, R15 and R16 that are attached to adjacent carbon atoms on the benzene ring together with the carbon atoms to which they are attached form a C₃-C₁₀cycloaliphatic ring, a 5- or 6-membered heterocyclic ring wherein at least one of the ring atoms is nitrogen, oxygen or sulphur, or a benzene ring optionally substituted by halo, cyano, hydroxy, carboxy, aminocarbonyl, nitro, C1-C10-alkyl, C1-C10-alkoxy or C3-C10cycloalkyl;

n⁴ is an integer from 0 to 4;

R¹⁷ and R¹⁸ are independently -CR³⁰R³¹-, -CH₂-CH₂-, -CH₂-CH₂-, -O-, -CH₂-O-, -CH₂-O-CH₂-, -S-, -SO-, -SO₂-, -CH₂-S-, -CH₂-CH₂-S-, -CH₂-SO-, -CH₂-SO₂- or a bond; R¹⁹ is hydrogen or C₁-C₁₀-alkyl optionally substituted by C₁-C₁₀-alkoxy, C₇-C₁₅-aralkyloxy, a C₅-C₁₅-carbocyclic group or by a 5- or 6-membered heterocyclic group wherein at least one of the ring atoms is nitrogen, oxygen or sulphur;

or when R18 is -CR30R31-, R19 and R18 form a C5-C15-carbocyclic group;

 R^{20} and R^{21} form a 5- or 6-membered heterocyclic ring wherein at least one of the ring atoms is nitrogen, oxygen or sulphur, that ring being optionally substituted by halo, oxo, cyano, hydroxy, carboxy, aminocarbonyl, nitro, a C5-C15-carbocyclic group, C7-C15-aralkyl, C1-C10-alkyl optionally substituted by C3-C10-cycloalkyl, or C1-C10-alkoxy optionally substituted by C3-C10-cycloalkyl;

 R^{30} and R^{31} are independently hydrogen, C_1 - C_{10} -alkyl or C_1 - C_{10} -alkoxy, either of which being optionally substituted by a C5-C15-carbocyclic group;

n⁵ is an integer from 0 to 4; and

at least one of R²², R²³, R²⁴ and R²⁵ is a 5- to 12-membered heterocyclic ring wherein at least one of the ring atoms is nitrogen, oxygen or sulphur, that ring being optionally and independently substituted by halo, cyano, hydroxy, carboxy, aminocarbonyl, nitro, C1-C10alkyl, C1-C10-alkoxy or C3-C10-cycloalkyl,

the other or others of R²², R²³, R²⁴ and R²⁵ being independently hydrogen, halo, cyano, hydroxy, carboxy, aminocarbonyl, nitro, C1-C10-alkyl, C1-C10-alkoxy or C3-C10-cycloalkyl.

2. A compound according to claim 1, where

-C~Y- is -CH=CH-;

R1 is hydroxy and R2 is hydrogen;

G is a group having the formula Ia, Ib, Ic, Id or Ie;

when n¹ is 0, R^a is -CR²⁶R²⁷-, -CH₂-CH₂-, -CH₂-CH₂-, -CH₂-CH₂-, -CH₂-O-CH₂- or -CH₂-CH₂-S-, n^1 is 0 or 1; and Rb is -CR28R29-, -CH2-O- or a bond,

otherwise when n^1 is 1, R^a and R^b are both $-CR^{26}R^{27}$ -;

Re is hydrogen or C1-C10-alkyl optionally substituted by a C5-C15-carbocyclic group or by

or when Rb is -CR26R27- or -CR28R29-, Rc and Rb form a C5-C15-carbocyclic group; C1-C10-alkoxy, R3, R4, R5 and R6 are independently hydrogen, C1-C10-alkyl or C1-C10-alkoxy; R²⁶, R²⁷ and R²⁸ are independently hydrogen, C₁-C₁₀-alkyl, C₁-C₁₀-alkoxy or a 5- or 6membered heterocyclic ring wherein at least one of the ring atoms is nitrogen, oxygen or sulphur;

 R^{29} is C_1 - C_{10} -alkyl or C_1 - C_{10} -alkoxy;

 n^2 is 0;

C~C denotes C=C or CH-CH;

R7 and R8 are both hydrogen;

 $m R^9$ and $m R^{10}$ are independently hydrogen or $m C_1$ - $m C_{10}$ -alkyl,

or R^9 and R^{10} together form a C_3 - C_{10} -cycloalkyl or C_3 - C_{10} -cycloalkenyl in either case optionally substituted by C1-C10-alkyl;

R¹¹ is hydrogen, hydroxy, a C₃-C₁₅-carbocyclic group or C₁-C₁₀-alkyl optionally substituted by a C3-C15-carbocyclic group;

 R^{12} is C_1 - C_{10} -alkyl substituted by C_1 - C_{10} -alkoxy, C_7 - C_{15} -aralkyloxy or by a C_5 - C_{15} n^3 is 0; carbocyclic group;

R¹³, R¹⁴, R¹⁵ and R¹⁶ are independently hydrogen or C₁-C₁₀-alkyl;

n4 is 0 or 1;

R¹⁷ and R¹⁸ are both methylene;

 R^{20} and R^{21} form a 5- or 6-membered heterocyclic ring wherein at least one of the ring R19 is hydrogen; atoms is nitrogen, oxygen or sulphur, that ring being optionally substituted by oxo, C7-C15aralkyl or C1-C10-alkyl optionally substituted by C3-C10-cycloalkyl;

at least one of R²², R²³, R²⁴ and R²⁵ is a 5- to 12-membered heterocyclic ring wherein at least n5 is 0; and one of the ring atoms is nitrogen, oxygen or sulphur, that ring being optionally and independently substituted by halo or C1-C10-alkyl, the other or others of R²², R²³, R²⁴ and R²⁵ being hydrogen.

3. A compound according to claim 2, where

-C~Y- is -CH=CH-;

R1 is hydroxy and R2 is hydrogen;

when n^1 is 0, R^a is $-CR^{26}R^{27}$ -, $-CH_2$ - CH_2 -, $-CH_2$ - CH_2 -, $-CH_2$ - CH_2 -, $-CH_2$ -O- $-CH_2$ - or $-CH_2$ -CH₂-S-, and Rb is -CR28R29-, -CH2-O- or a bond, otherwise when n1 is 1, Ra and Rb are both -CR26R27-;

Re is hydrogen or C1-C4-alkyl optionally substituted by a C5-C10-carbocyclic group or by

or when Rb is -CR26R27- or -CR28R29-, Re and Rb form a C5-C10-carbocyclic group; R^3 , R^4 , R^5 and R^6 are independently hydrogen, C_1 - C_4 -alkyl or C_1 - C_4 -alkoxy;

R²⁶, R²⁷ and R²⁸ are independently hydrogen, C₁-C₄-alkyl, C₁-C₄-alkoxy or a 5- or 6membered heterocyclic ring wherein at least one of the ring atoms is nitrogen, oxygen or sulphur;

R²⁹ is C₁-C₄-alkyl or C₁-C₄-alkoxy;

 n^2 is 0;

C-C denotes C=C or CH-CH;

R7 and R8 are both hydrogen;

R9 and R10 are independently hydrogen or C1-C4-alkyl,

or R5 and R6 together form a C3-C6-cycloalkyl or C3-C6-cycloalkenyl in either case optionally substituted by C1-C4-alkyl;

 R^{11} is hydrogen, hydroxy, a C_3 - C_{10} -carbocyclic preferably C_3 - C_6 -cycloalkyl, or C_1 - C_{10} -alkyl optionally substituted by a C_3 - C_{10} -carbocyclic group preferably an unsaturated C_5 - C_8 carbocyclic group;

 n^3 is 0;

 R^{12} is C_1 - C_{14} -alkyl substituted by C_1 - C_6 -alkoxy, C_7 - C_{10} -aralkyloxy or by a C_5 - C_{10} carbocyclic group;

R13 and R16 are both hydrogen;

 R^{14} and R^{15} are independently hydrogen or $C_1\text{-}C_4\text{-}alkyl$.

n4 is 0 or 1;

R¹⁷ and R¹⁸ are both methylene;

 R^{20} and R^{21} form a 5- or 6-membered heterocyclic ring wherein at least one of the ring R¹⁹ is hydrogen; atoms is nitrogen, oxygen or sulphur, that ring being optionally substituted by oxo, C7-C10aralkyl or C1-C4-alkyl optionally substituted by C3-C6-cycloalkyl.

at least one of R²², R²³, R²⁴ and R²⁵ is a 5- to 9-membered heterocyclic ring wherein at least n⁵ is 0; and one of the ring atoms is nitrogen, oxygen or sulphur, that ring being optionally and independently substituted by halo or C1-C4-alkyl, the other or others of R²², R²³, R²⁴ and R²⁵ being hydrogen.

- 4. A compound according to claim 1 substantially as herein described with reference to any one of the Examples.
- 5. A compound according to any one of the preceding claims in combination with another drug substance which is an anti-inflammatory, a bronchodilator, an antihistamine or an immunosuppressive or anti-tussive drug substance.
- 6. A compound according to any one of the preceding claims for use as a pharmaceutical.
- 7. A pharmaceutical composition comprising a compound according to any one of claims 1 to 5, optionally together with a pharmaceutically acceptable carrier.
- 8. Use of a compound according to any one of claims 1 to 5 for the preparation of a medicament for the treatment of a condition which is prevented or alleviated by activation of the β_2 -adrenoreceptor.

- 9. Use of a compound according to any one of claims 1 to 5 for the preparation of a medicament for the treatment of an obstructive or inflammatory airways disease.
- 10. A process for the preparation of a compound of formula I in free or salt or solvate form comprising:
- (A) reacting a compound of formula II (i)

or a protected form thereof wherein -C-Y-, R1 and R2 are as hereinbefore defined, with a compound of formula III

where G is a group of formula Ia, Ib, Ic, Id or Ie

or a protected form thereof wherein n1, n2, n3, n4, n5, Ra, Rb, Rc and R3 through R25 are as hereinbefore defined; or

(B) reducing a compound of formula IV

or a protected form thereof wherein -C~Y-, R1, R2 and G are as hereinbefore defined, to convert the indicated keto group into -CH(OH); or

(C) for the preparation of compounds of formula I where G is a group of formula Ia, R^c is hydrogen and n^1 is 0, reacting a compound of formula V

or a protected form thereof wherein -C~Y-, R¹ and R² are as hereinbefore defined, with a compound of formula VI

$$Q = \begin{bmatrix} R^3 & R^4 & VI \\ R^6 & R^5 \end{bmatrix}$$

or a protected form thereof wherein Ra, Rb, R3, R4, R5 and R6 are as hereinbefore defined; or

(D) for the preparation of compounds of formula I where G is a group of formula 1d, R¹⁹ is hydrogen and n⁴ is 0, reacting a compound of formula V or a protected form thereof wherein -C~Y-, R¹ and R² are as hereinbefore defined, with a compound of formula VII

$$0 = R^{17} + R^{20}$$
 VIII

or a protected form thereof wherein R^{17} , R^{18} , R^{20} and R^{21} are as hereinbefore defined; and

- (ii) recovering the resultant compound of formula I in free or salt or solvate form.
- 11. A compound of formula IV

in free or salt or solvate form, where -C-Y-, R1, R2 and G are as defined in claim 1.